Vernalis PLC Notice of Results (6771J)
September 13 2016 - 5:34AM
UK Regulatory
TIDMVER
RNS Number : 6771J
Vernalis PLC
13 September 2016
13 September 2016
Vernalis plc ("Vernalis" or the "Company")
Notice of Full Year Results
Vernalis plc (LSE: VER) announces its audited financial results
for the year ended 30 June 2016 will be released on Thursday 29
September 2016. The results announcement will be distributed at
7:00 am (UK) and will be available to download from
www.vernalis.com.
Following the results announcement, the Company will host an
analyst presentation and concurrent conference call at 9:30 am (UK)
at the offices of FTI Consulting, 200 Aldersgate, Aldersgate
Street, London, EC1A 4HD. Please contact Matthew Moss at FTI
Consulting +44 (0) 20 3727 1000 for details.
-- ends --
Enquiries:
Vernalis plc:
Ian Garland, Chief Executive +44 (0) 118 938
Officer 0015
David Mackney, Chief Financial
Officer
Canaccord Genuity Limited +44 (0) 20 7523
(Nominated Adviser): 8000
Dr Julian Feneley
Henry Fitzgerald-O'Connor
Rupert Winckler
Emma Gabriel
+44 (0) 20 7408
Shore Capital (Joint Broker): 4090
Bidhi Bhoma
Toby Gibbs
+44 (0) 20 3727
FTI Consulting: 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR
targeting the US prescription cough cold market; MOXATAG(R) , a
once-a-day formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes and frovatriptan for the acute treatment of
migraine. It has an exclusive licensing agreement to develop and
commercialise multiple novel products focussed on the US
prescription cough cold market as well as eight programmes in its
NCE development pipeline. Vernalis has also significant expertise
in fragment and structure based drug discovery which it leverages
to enter into collaborations with larger pharmaceutical companies.
The Company's technologies, capabilities and products have been
endorsed over the last five years by collaborations with leading
pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and
Tris.
For further information about Vernalis, please visit
www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that
reflect the Company's current expectations regarding future events
including the clinical development and regulatory clearance of the
Company's products, the Company's ability to find partners for the
development and commercialisation of its products, as well as the
Company's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a
number of factors including the success of the Company's research
strategies, the applicability of the discoveries made therein, the
successful and timely completion of clinical studies, the
uncertainties related to the regulatory process, the ability of the
Company to identify and agree beneficial terms with suitable
partners for the commercialisation and/or development of its
products, as well as the achievement of expected synergies from
such transactions, the acceptance of frovatriptan and other
products by consumers and medical professionals, the successful
integration of completed mergers and acquisitions and achievement
of expected synergies from such transactions, and the ability of
the Company to identify and consummate suitable strategic and
business combination transactions.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOREANNDFDEKEEF
(END) Dow Jones Newswires
September 13, 2016 05:34 ET (09:34 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vernalis (LSE:VER)
Historical Stock Chart
From Oct 2023 to Oct 2024